A carregar...
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study
Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is <18 months. This study was designed to determine if maintenance lenalidomid...
Na minha lista:
| Publicado no: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5923897/ https://ncbi.nlm.nih.gov/pubmed/26913697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13957 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|